Learn about how different healthcare providers work together to help breast cancer patients weigh their treatment options.

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

The FDA has approved Imfinzi® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with MIBC.

Sep. 9, 2024 — The risk of skin cancer for adults under the age of 50 is now decreasing for the first time in ... Age-Related Changes in Male Fibroblasts Increase Treatment-Resistant Melanoma ...

The Miami-based company isn't alone in making that bet. Gannon University and Saint Vincent Hospital announced plans Wednesday to develop two new laboratories inside Gannon's Institute for ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

NICE has rejected Pfizer’s Ibrance breast cancer drug in first draft guidance, citing the treatment's high cost. The decision confirms the company’s fears that the drug would fare badly under ...

Radiation exposure. If your head or neck was exposed to radiation treatment as a child, you could have a higher cancer risk. There isn't a screening test for thyroid cancer. Your doctor may find ...

Clinical trials test the safety and effectiveness of new cancer drugs and treatments. They help us find better ways to prevent, diagnose, and treat cancer. Nearly all current cancer treatments started ...

However, you may have heard some conflicting information about soy and cancer risk. You might have questions like, “Is soy healthy? Is it dangerous? And if it’s OK to eat soy foods, why do some people ...

Itovebi, combined with Ibrance and Faslodex, is approved for specific advanced breast cancer cases with PIK3CA mutations ... The Itovebi combination regimen was approved in October 2024 for the ...